Amarin stock doubled today on its second round of positive phase III results with its triglyceride drug, AMR101. The drug met primary and secondary endpoints in its second phase III trial. Patients showed a significant drop in triglycerides with no rise in LDL-C - so-called "bad cholesterol". It also caused a reduction in significant markers of cardiovascular risk like Apo B and non-HDL-C. AMR-101 is a modified form of omega-3 fish oil.
"The design and execution of the Anchor trial were robust and the trial results were very clearly positive," said Christie M Ballantyne, MD, principle investigator. Amarin may submit its NDA for AMR101 in Q3 this year and seek approval by Q2 2012. See Fierce Biotech.
Posted by Bruce Lehr April 18th 2011.